SPRY
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
ARS Pharmaceuticals, Inc. (SPRY) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Revisions (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B- (3.0) | B- (3.1) | C (2.4) | D (1.4) | F (0.0) | C- (2.0) |
| 2026-11-08 | B- (3.0) | B (3.2) | C+ (2.6) | D- (1.1) | F (0.0) | C- (2.0) |
| 2026-11-01 | B- (3.0) | A- (3.9) | C+ (2.8) | D (1.3) | C+ (2.7) | C+ (2.7) |
| 2026-10-25 | B- (3.0) | A- (3.9) | C+ (2.8) | D (1.3) | C+ (2.6) | C+ (2.7) |
| 2026-10-18 | B- (3.0) | A- (3.9) | C+ (2.8) | D (1.2) | C+ (2.6) | C+ (2.7) |